Wedbush Maintains Outperform on Larimar Therapeutics, Lowers Price Target to $11

Benzinga Newsdesk www.benzinga.com Negative 95.1%

Neg 95.1% Neu 0% Pos 0%

Wedbush analyst Laura Chico maintains Larimar Therapeutics (NASDAQ:LRMR) with a Outperform and lowers the price target from $12 to $11.